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Abstract
Background There is increasing interest in involving patient preferences for benefits and risks in regulatory decision mak-
ing. Therefore, it is essential to identify patient perspectives regarding the value of patient preference information (PPI).
Objectives The aim of this study was to explore how patients with rheumatoid arthritis (RA) value the use of PPI in regula-
tory decision making regarding medical products.
Methods Regulators and patients with RA were interviewed to gather initial insights into opinions on the use of PPI in 
regulatory decisions regarding medical products. The interviews were used to draft and validate the interview guide for 
focus groups with patients with RA. Participants were purposively sampled in collaboration with the Swedish Rheumatism 
Association in Stockholm and Uppsala. Each focus group consisted of three to six patients (18 in total). All interviews were 
audio-recorded, transcribed verbatim, and analysed using content analysis.
Results According to the participants, PPI could lead to regulators considering patients’ needs, lifestyles and well-being 
when making decisions. PPI was important in all stages of the medical product lifecycle. Participants reported that, when 
participating in a preference study, it is important to be well-informed about the use of the study and the development, com-
ponents, administration, and risks related to the medical products.
Conclusions Patients thought PPI could be valuable to consider in regulatory decisions. It is essential for patients to be 
well-informed when asked for their preferences. Research on information materials to inform patients in preference studies 
is needed to increase the value of PPI in regulatory decision making.
Key Points for Decision Makers 
Patients thought it was important to be involved in regu-
latory decisions and that patient preference information 
(PPI) could be valuable to consider when including their 
preference.
PPI in regulatory decisions may ultimately lead to 
compliance with treatment, which could improve clinical 
outcomes in patients with rheumatoid arthritis.
Adequately informing patients about the medical prod-
uct characteristics included in a preference study can 
increase the value of PPI in regulatory decision making.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4027 1-018-0344-2) contains 
supplementary material, which is available to authorized users.
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1 Introduction
Traditionally, regulatory decision making has attempted to 
balance the risks and benefits of medical products accord-
ing to the outcomes of clinical trials. However, as regu-
lators have come to recognise that they may not assign 
the same value to risks and benefits as would patients, 
they have begun to emphasise patients’ perspectives [1]. 
Moreover, patients’ perspectives regarding risks, benefits, 
and treatment procedures vary [2, 3]. For example, not all 
patients would accept higher risks to gain a small benefit 
[4]. Patient perspectives are occasionally included in regu-
latory decision making via the inclusion of patient repre-
sentatives in decision boards and groups in the EU [3]. 
Different instruments have also been developed to elicit 
and include patients’ experiences, such as patient-reported 
outcomes, which measure clinically meaningful endpoints. 
However, these methods cannot capture the relative impor-
tance of different clinical endpoints or how patients make 
trade-offs between risks and benefits [5].
The increasing interest in involving patients’ perspec-
tives on risks and benefits has inspired the development of 
new methods that elicit and measure preferences in patient 
populations [1, 6]. To quantify the relative importance of 
medical product characteristics, methods such as discrete-
choice experiments (DCEs) ask patients to choose treat-
ment attributes [7]. In addition, patient perspectives can 
be assessed using patient preference information (PPI). 
According to the US FDA, PPI is “qualitative or quantita-
tive assessments of the relative desirability or acceptabil-
ity to patients of specified alternatives or choices among 
outcomes or other attributes that differ among alternative 
health interventions” [2]. PPI has been reported to sup-
port risk–benefit decisions by transparently framing issues 
from the patient’s perspective [8, 9] and by identifying 
subgroups when preferences differ [10].
In both the EU [1] and the USA [6], regulatory agencies 
have acknowledged a need for more research that inves-
tigates how patient preferences are assessed. Moreover, 
agencies have not established best practices (i.e., the PPI 
methods to use in regulatory decision making), when to 
use PPI, or how best to conduct patient-preference studies. 
Although regulatory agencies recognize the value of PPI, 
few studies have evaluated how patients view the use of 
PPI for regulatory decision making. Patients’ perspectives 
on PPI can provide input that can be used when recom-
mending how to measure and implement PPI in regulatory 
decisions for drugs and devices in the medical product 
lifecycle (MPLC) [5, 9, 11].
This article focuses on the perspectives of patients with 
rheumatoid arthritis (RA) on the value of including PPI in 
regulatory decisions regarding (new) disease-modifying 
antirheumatic drugs (DMARDs). RA—a chronic inflam-
matory autoimmune disease—is characterised by ten-
derness, swelling, and destruction of joints, which can 
result in disability and premature death [12]. The indi-
vidual burden includes decline in physical function, caus-
ing musculoskeletal deficits and reduced work capacity, 
resulting in high socioeconomic burden. Early treatment 
with DMARDs can control and prevent negative outcomes 
such as pain, stiffness, fatigue, fever, weakness, deformity, 
malaise, weight loss, and depression [13, 14]. Because 
patients with RA are familiar with the disease, treatments, 
and side effects, their experiences can contribute to under-
standing how best to use PPI in regulatory decision mak-
ing. The aim of this study was to explore how patients with 
RA value the use of PPI in regulatory decision making 
regarding medical products.
2  Methods
A two-step approach was used to explore how patients with 
RA value the use of PPI in regulatory decision making for 
medical products. First, semi-structured interviews with reg-
ulators and patients were conducted to develop an interview 
guide. Second, focus groups were conducted with patients 
with RA in Stockholm and Uppsala, Sweden. The study was 
approved by the regional ethics review board in Uppsala, 
Sweden (Reg. no. 2017/001). All participants in the inter-
views and focus groups provided written informed consent.
2.1  Semi‑Structured Interviews with Regulators 
and Patients
Initially, four regulators from the Swedish Medical Products 
Agency were individually interviewed to map the current 
involvement of patients’ preferences and the potential use 
of PPI in regulatory decision-making processes. An inter-
view guide was developed in collaboration with the PRE-
FER (Patient Preferences in Benefit-Risk Assessments in 
the Drug Lifecycle) project [15]. A selection of questions 
from the interview guide were used in this study because 
we focused on the regulatory process. The interviewees 
came from a pool of regulators in Sweden working with 
risk and benefit decisions at the national or EU level (i.e., at 
the Medical Products Agency and the European Medicines 
Agency). An invitation was emailed to these regulators, and 
all interviews were conducted face-to-face with the first 
author (KSB).
In addition, five patients with RA were interviewed to 
gather preliminary insights into patients’ knowledge and 
opinions on the use of PPI in regulatory decision making. 
These interviews used another interview guide developed in 
the PREFER project. The guide was developed for patients, 
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caregivers, and patient representatives and included ques-
tions about the participants’ views on conducting and using 
the results from patient-preference studies in the MPLC. 
Patients in this study were purposively selected using the 
following inclusion criteria: aged 18–80 years, established 
RA diagnosis reflecting one of the stages of treatment, and 
representing an RA patient organisation. The following 
patients were selected for interviews: one patient represent-
ing a patient organisation, one patient who was newly diag-
nosed (i.e., within 6 months), one patient treated with at 
least one synthetic DMARD, one patient receiving at least 
one biological DMARD, and one patient treated with syn-
thetic and biological DMARDs. These patients were asked 
to participate in the interviews by their rheumatologist at 
Uppsala University Hospital. Invitations were sent via email 
to patients who volunteered to participate. The interviews 
were conducted by the first author (KSB) at Uppsala Uni-
versity or at the participants’ workplace.
2.1.1  Analysis of Semi‑Structured Interviews
The first author (KSB) conducted, audio-recorded, and 
transcribed the interviews, which were then analysed using 
content analysis [16]. Coding and analysis of the interviews 
were mainly performed by the first author (KSB) and the 
last author (UK), and results from both authors were com-
pared and combined in discussion with all of the authors. 
All authors reached consensus on the codes, sub-categories, 
and main categories. This consensus generated topics for 
further exploration in focus groups with patients with RA. 
The analysis of the regulatory interviews revealed several 
themes: patient involvement in the regulatory process, 
the value of patient preferences in the regulatory process, 
patient preferences in the MPLC, methods for measuring 
patient preferences, and the need to inform patients. The 
regulatory interviews were also used to draft the educational 
material for the focus groups. Analysis of the patient inter-
views revealed the following themes: patient preferences in 
the regulatory process, patient preferences in the MPLC, 
methods for measuring patient preferences, and the need 
to inform patients. Results from the patient interviews and 
from the regulatory interviews were reviewed by all of the 
researchers. All authors reached consensus on three topics 
and questions for the interview guide for focus groups with 
patients with RA (Table 1).
2.2  Focus Groups
Four focus groups with patients with RA were conducted to 
explore the perspectives of patients on the value of PPI in 
regulatory decisions. Ta
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2.2.1  Recruitment
Patients were purposively sampled from the Swedish Rheu-
matism Association in Stockholm and Uppsala. To ensure a 
mix of patients, the following inclusion criteria were used: 
aged 18–80 years, established RA diagnosis, and different 
stages of treatment. The Swedish Rheumatism Association 
in Stockholm and Uppsala sent invitations to patients. Each 
focus group consisted of three to six patients (18 in total).
2.2.2  Conducting of Focus Groups
Results from the semi-structured interviews were used to 
draft the interview guide for the focus groups. The guide 
was pre-tested using a pilot focus group (n = 4) and refined 
before the final focus groups were conducted. The interview 
guide consisted of the following topics: perceived value of 
RA patient preferences in the regulatory process, operation-
alisation of preference studies, and perceived need among 
patients to be informed. The focus groups were conducted 
by the first author (KSB) in Swedish, and an assistant took 
notes. The last author participated as an assistant in two 
of the focus groups. Before ending the focus group, the 
assistant summarised the discussion and gave the partici-
pants an opportunity to clarify what they said. The Swedish 
Rheumatism Association in Stockholm and Uppsala pro-
vided their facilities for two focus groups each. The focus 
groups lasted ~ 120 min, including a 20-min presentation of 
the regulatory process and the potential to include PPI. The 
information provided in the presentation was identified using 
the semi-structured interviews.
2.2.3  Data Analysis
All focus groups were audio-recorded and transcribed ver-
batim. Data collection and analyses were performed concur-
rently by starting the analysis right after the first interview to 
estimate when thematic saturation was reached. A qualita-
tive content analysis with a manifest and inductive approach 
was applied to analyse the focus groups [16]. In a first step, 
the transcripts were independently coded by two researchers 
(KSB, UK) to develop an initial list of codes. In this step, 
relevant fragments of text were extracted and coded. Similar 
codes that belonged to the same content were then grouped 
into potential sub-categories and main categories. Second, 
investigator triangulation was obtained in further analysis by 
discussing all potential sub-categories and main categories 
with all authors to further refine the list of codes. When 
all authors reached consensus, the refined list of codes was 
entered into the program NVivo 11 together with transcripts 
of the focus groups. The list of codes included 40 codes, 11 
sub-categories, and three main categories (Table 2). After 
the content from the transcripts was coded, it was entered 
into NVivo. When the data were structured according to the 
list of codes, the authors (KSB, UK) independently sum-
marised the quotations. These summaries were discussed 
among all of the authors and revised into a result. Meaning-
ful quotations were selected from the data and translated into 
English to illustrate the relevance of the result.
3  Results
Most participants were highly educated females aged 
28–79 years (mean 59). The duration since RA diagnosis 
was 1–42 years (Table 3).
3.1  Value of Using Rheumatoid Arthritis Patient 
Preference Information (PPI) in Regulatory 
Decisions
Participants in the focus groups discussed the fact that 
patients should have the right to influence regulatory 
decisions:
“I actually think that you should claim the right to an 
opinion.”
In addition, they discussed that studies that elicit patient 
preferences can provide them the opportunity to express 
their opinion. Several participants said it was important for 
regulators to consider patients’ preferences when making 
decisions because patients may have varying preferences 
about what risks and benefits they want to consider:
“It might be the case that patients explain that they are 
willing to do different things. I mean that they value 
this differently, that it’s okay to have some side effects 
as long as the benefit is greater, but other side effects 
may not be okay at all in the long run. I don’t know. I 
think that decision makers might have a different view 
of benefits and risks than patients. So, it might be good 
for them to be given a voice there.”
Participants also said that patient-preference studies could 
provide information to regulators about valuable characteris-
tics for treatment from a great number of patients:
“The more patients influencing these decisions, the 
better, and if we say that this doesn’t work, they need 
to do something about it. Well, I think that before 
experts make up their minds, they should get informa-
tion from patients.”
Currently, available treatments do not fit all participants’ 
needs, lifestyles, and well-being. Some participants shared 
their experiences of unbearable side effects that made them 
stop their treatments:
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“From everything I went through, they completely 
failed me on this, you might say. They did for me, in 
this case. And I talked to my doctor and it wasn’t just 
me, it was plenty of people. It was the same thing. So, 
that went totally wrong, and it makes you wonder.”
Table 2  List of codes
PPI patient preference information, RA rheumatoid arthritis
Codes Sub-categories Main categories
Patient influence decisions Benefits with patient preferences in decisions Values of using RA PPI in regulatory decisions
Patients’ rights to be involved in decisions
Patient-friendly medical products benefit 
patients
Economic benefits for society
Representativeness
Limited regulatory view Limitations with patient preferences in deci-
sionsPatient heterogeneity
Knowledge about RA
Patient-friendly medical products for RA Value of patient preferences in RA-related 
decisionsChronic condition
High prevalence
Life style
Quality of life for patients with RA
Patient satisfaction Future expectations
Patient-friendly medical products for all 
patients
Quality of life improvements
Compliance with medical products
Better decisions and treatments
Economic expectations
Not by pharmaceutical companies Concerns Operationalisation of patient-preference studies
Drug discovery When to conduct
Clinical trials
Application
Evaluation
Decision
Post-approval
Mixed group Participants
Time from symptoms to diagnosis
Experience
Information about product development Medical products Information needs in a preference study
Information about medical product
Information about administration
Information about side effects
Information about risks
Information about RA RA information
Use of results Aim
Information about regulatory process
Online Communication format
Offline
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Participants also mentioned some limitations with PPI, 
such as the limited knowledge patients have regarding 
medical products. According to some participants, this can 
result in an incorrect view among regulators of what patients 
prefer:
“I’m a bit hesitant about this, since my perspective is 
that we all have different medications, so what are we 
going to tell them then?”
Another limitation related to the ways in which patients 
with RA differ: disease trajectories, symptoms, and treat-
ments, response to treatments, and side effects experienced:
“That one medicine doesn’t work on the other person 
and the disease trajectory isn’t the same for every-
body.”
Several participants stated that patients might have dif-
ferent preferences:
“Because people are very different, and the most 
important preferences are of course that the treatment 
can help, and that they have an effect, and that there 
are as few side effects as possible. The decision makers 
should also be aware that people are different.”
Many participants said it was important to include PPI 
specifically in regulatory decisions regarding RA as RA is a 
chronic condition with a high prevalence:
“I would say that, maybe, it is extra important for RA 
because it is a chronic condition that has no cure.”
Some participants stated that regulators should use PPI 
in decisions because patients with RA have more knowledge 
than regulators about their needs, lifestyles, and well-being:
“We are the ones with this disease; we know a lot 
about it and how it makes us feel. I think, because of 
that, they should take our opinions into consideration 
more often.”
Furthermore, some participants said PPI might contribute 
to improved product efficacy and usability with respect to 
patients’ lifestyles:
“Maybe more thorough decisions, so to speak, that you 
[…] yes […] if they consider this for a longer time. So, 
this is the patient’s preference and we also need to take 
this into consideration.”
That is, medical products based on patient feedback might 
improve patient compliance with treatment. In addition, par-
ticipants said that compliance might make it more likely that 
they would return to their daily lives and work, further eas-
ing the socioeconomic burden associated with RA:
“Well, these past 9 months, with so many things, I 
mean, I was going to […] I was just lying there, just 
like in a coma from this medication. I couldn’t work or 
do anything, which was just silly, I mean, that wasn’t 
really saving money.”
3.2  Operationalisation of PPI
Participants had different ideas on where in the MPLC it 
is most important to conduct patient-preference studies in 
order for PPI to be incorporated in regulatory decisions. 
When it comes to designing patient-friendly products, some 
participants said PPI is most important for drug discovery, 
but other participants said PPI is most important for clinical 
trials or the application phase:
“Possibly in clinical trials, if there’s a possibility to 
provide something that a lot of people want, but they 
don’t know.”
Most participants discussed that PPI should be incorpo-
rated into risk–benefit evaluations because regulators make 
objective decisions on whether to approve a product:
“Absolutely before the decision so the experts conduct-
ing evaluations know what patients prefer.”
Although participants said that PPI can benefit the 
development of patient-friendly products, they expressed 
concerns regarding pharmaceutical companies conducting 
studies. That is, some believed that pharmaceutical com-
panies might care only about profits and “lie to patients”:
“Yes, I thought so, it’s both for and against, but I don’t 
really trust the pharmaceutical companies, because it 
appears that they lie sometimes, so that’s what I’m 
thinking about.”
Table 3  Patients in focus groups (N = 18)
a Unless otherwise indicated
Characteristic Na
Sex
 Female 17
 Male 1
Education level
 Low 5
 Medium 5
 High 8
Mean age (range), years 59 (28–79)
Years with RA (range) 1–42
Interview location
 Stockholm 11
 Uppsala 7
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Another participant expressed similar pessimism:
“I don’t think the first steps are relevant because they 
are linked to the pharmaceutical company.”
All of the groups discussed the importance of including a 
mixed group of patients regarding sex, age, socioeconomic 
position, and lifestyle in the preference studies:
“Yes, they should absolutely be of different ages and 
sexes and […] yes, different occupations and different 
life situations, and how long you’ve had the disease 
and things like that. It’s really important that it’s not a 
homogenous group.”
Many participants emphasised that patient-preference 
studies need to include patients with experience of the dis-
ease and of treatments:
“Yes, then you can’t have recently diagnosed patients; 
it won’t work. Experience with the disease and offering 
valuable insights requires you to have had it for some 
time and to have tried different things.”
3.3  Information Needs in a Preference Study
The participants discussed that patients need to be informed 
about how the results will be used and where in the regula-
tory process a study will have an influence:
“I would like to know if it’s before a decision, or if it’s 
already decided; then it is what it is, then I might not 
be able to have an influence the same way as before 
the decision.”
They also said patients should be given information about 
RA and the medical products—e.g., their development, com-
ponents, administration, and risks—before participating in 
a preference study:
“I would like to know how this medical product acts in 
the body. What does it do and what is happening, what 
are the possible side effects?”
Most of the participants said they prefer written infor-
mation and questionnaires over interviews because it gives 
them time to go back and think about their answers:
“Because then you can go back and forward and think 
about it; you can return to the questions another day.”
Online surveys might be suitable, according to some par-
ticipants, since they allow for more flexible interactivity with 
the questionnaire. They also said that online surveys might 
be more convenient for patients with RA to answer, because 
it is easier for them to press buttons than to write with a pen:
“With our disease especially, it’s easier to press a but-
ton than to write.”
4  Discussion
The use of PPI in regulatory decision making regarding 
medical products has been emphasised in several initiatives 
to investigate methods that elicit patient preferences for reg-
ulatory decisions [1, 6]. This study brings a new aspect to 
this perspective by asking patients about their view on PPI 
in regulatory decision making.
The main finding in this study was that patients think PPI 
could provide valuable information for regulatory decision 
making. According to the participants, PPI could benefit 
both the patients and the regulators in that the regulators 
could take patients’ needs, lifestyles, and well-being into 
consideration when evaluating and approving (including 
post-approval) medical products. Both stakeholders could 
also benefit from PPI through the ability to identify and 
value important treatment characteristics for patients, as 
regulators may not be adequately informed about patient 
perspectives when only referring to the results of clinical 
trials. For example, PPI can provide information about the 
relative importance of different medical product character-
istics. This finding is consistent with previous findings that 
PPI is important to consider in regulatory decisions [10, 17].
The participants also discussed possible limitations with 
PPI, such as an inability to capture how patients differ in 
their preferences because the preferences of patients with 
RA do vary [18]. However, preference studies can make it 
possible to present how preferences differ within subgroups 
of the patient population. Methods that elicit patient prefer-
ences, such as DCEs, can also quantify the relative impor-
tance of risks and benefits of medical products and make the 
information valuable for regulatory decisions [10].
In addition, participants expressed that PPI should be 
used to complement information from clinical trials. This 
finding is in line with those of previous research, that regula-
tors should consider how patients weigh risks and benefits 
when making regulatory decisions [1]. Participants also rec-
ognise that the risk and benefit evaluation is an important 
step in the MPLC for implementing the use of PPI. Patients 
may adopt this reasoning because they do not want market 
approval for medical products that could expose them to a 
certain side effect [4].
Some participants expressed concern about pharmaceuti-
cal companies conducting patient-preference studies, with 
some thinking pharmaceutical companies should not be 
involved in conducting preference studies. One reason for 
expressing this concern might be a worry that pharmaceu-
tical companies introduce bias to PPI. Other participants 
thought it would be good for pharmaceutical companies 
to have the information early in the product-development 
process.
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A third finding was the identified need to inform partici-
pants in preference studies about the use of the study, the 
disease, and the medical product’s characteristics. Partici-
pants may have expressed a need for information because it 
was important to them that patient preferences used in regu-
latory decision making are representative and well-informed. 
This need for information may also relate to their desire that 
participants in preference studies represent a range of expe-
riences with the disease and its treatments. However, ade-
quately informing patients about the medical product char-
acteristics included in the preference study might decrease 
this concern by increasing the participants’ ability to make a 
well-informed choice when answering the questions.
This study has several limitations. Patients in the focus 
groups were approached by their patient organisation, which 
could influence their perspective toward including PPI in 
regulatory decision making. Another possible limitation is 
selection bias, since the patient sample mostly consisted of 
highly educated females aged > 50 years. Although this was 
partly expected because the prevalence of RA increases with 
age and is about twice as high in women as in men [19], it 
might have slightly influenced study outcomes.
5  Conclusions
Patients think it is important to be involved in regulatory 
decisions regarding medical products and believe that PPI 
could be a valuable tool for assessing the preferences of 
patients. When answering a preference study, it is essential 
that patients are well-informed about the use of preference 
data, the disease, and the medical product characteristics. 
Further research that focuses on methods for informing 
participants in a preference-elicitation study is needed to 
increase the value of PPI in regulatory decision making.
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